ArticleBMC cancer2026
PET/CT Radiomics-based assessment of tumor heterogeneity for predicting immunotherapy outcomes in advanced lung squamous cell carcinoma: a retrospective prognostic modeling study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurately predicting progression-free survival (PFS) in patients with advanced lung squamous cell carcinoma (LUSC) receiving immunotherapy remains a clinical challenge. Radiomics has emerged as a promising non-invasive approach; however, its application in this specific patient population remains relatively limited.
methodsA total of 129 patients were retrospectively enrolled. Radiomics features were extracted from baseline positron emission tomography/computed tomography (PET/CT) images. Feature reproducibility was evaluated using intraclass correlation coefficients (ICC), and only features with ICC > 0.75, indicating good reproducibility, were retained. A three-step feature selection strategy, including univariate Cox regression, least absolute shrinkage and selection operator (LASSO), and multivariate Cox modeling, was applied to construct the radiomics signature. Model performance was evaluated using time-dependent receiver operating characteristic (ROC) analysis, Kaplan-Meier survival analysis, and bootstrap resampling. Additionally, a 3D convolutional neural network (CNN) model was explored for comparative analysis.
resultsThe final model achieved a 2-year AUC of 0.673. The relatively stable AUC values across time points (1-year: 0.670; 2-year: 0.673; 3-year: 0.651) suggest that the model primarily captures baseline risk stratification rather than strong time-dependent variation. Patients in the high-risk group exhibited a significantly increased risk of progression compared with those in the low-risk group (HR = 4.36, 95% CI: 2.70-7.04, P < 0.001). The radiomics signature remained an independent predictor of PFS in multivariate analysis. In comparison, the 3D CNN model demonstrated inferior predictive performance compared with the radiomics-based model.
conclusionThe PET/CT-based radiomics model enables non-invasive risk stratification of patients with advanced LUSC receiving immunotherapy and may provide complementary information for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.